PE20110925A1 - Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida - Google Patents
Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundidaInfo
- Publication number
- PE20110925A1 PE20110925A1 PE2011000667A PE2011000667A PE20110925A1 PE 20110925 A1 PE20110925 A1 PE 20110925A1 PE 2011000667 A PE2011000667 A PE 2011000667A PE 2011000667 A PE2011000667 A PE 2011000667A PE 20110925 A1 PE20110925 A1 PE 20110925A1
- Authority
- PE
- Peru
- Prior art keywords
- alisquirene
- preparation
- felted
- dosage form
- formulation including
- Prior art date
Links
- 238000001125 extrusion Methods 0.000 title abstract 3
- 238000005469 granulation Methods 0.000 title abstract 2
- 230000003179 granulation Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 229960002900 methylcellulose Drugs 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9959508P | 2008-09-24 | 2008-09-24 | |
| US16179909P | 2009-03-20 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110925A1 true PE20110925A1 (es) | 2012-01-13 |
Family
ID=41323516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000667A PE20110925A1 (es) | 2008-09-24 | 2009-09-23 | Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110177166A1 (enExample) |
| EP (1) | EP2328562A1 (enExample) |
| JP (1) | JP2012503665A (enExample) |
| KR (1) | KR20110063684A (enExample) |
| CN (1) | CN102164584A (enExample) |
| AR (1) | AR073651A1 (enExample) |
| AU (1) | AU2009296718A1 (enExample) |
| BR (1) | BRPI0919077A2 (enExample) |
| CA (1) | CA2736259A1 (enExample) |
| CL (1) | CL2011000614A1 (enExample) |
| CO (1) | CO6351712A2 (enExample) |
| EC (1) | ECSP11010998A (enExample) |
| MA (1) | MA32722B1 (enExample) |
| MX (1) | MX2011003077A (enExample) |
| PE (1) | PE20110925A1 (enExample) |
| RU (1) | RU2011116122A (enExample) |
| TW (1) | TW201016210A (enExample) |
| WO (1) | WO2010036686A1 (enExample) |
| ZA (1) | ZA201101686B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR075880A1 (es) * | 2009-03-20 | 2011-05-04 | Novartis Ag | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo. |
| EP2382967A1 (de) * | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
| TWI657090B (zh) * | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| FR3055800B1 (fr) * | 2016-09-15 | 2020-06-26 | Unither Pharmaceuticals | Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules |
| CN114129569A (zh) * | 2020-09-04 | 2022-03-04 | 上海医药集团股份有限公司 | 一种含氮的饱和杂环化合物的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110121A1 (es) * | 2004-03-17 | 2011-02-28 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| AR050615A1 (es) * | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
| US20080075772A1 (en) * | 2006-04-13 | 2008-03-27 | Lawrence Solomon | Pharmaceutical compositions having novel scoring patterns and methods of using those compositions |
| PE20081157A1 (es) * | 2006-11-07 | 2008-09-26 | Novartis Ag | Forma cristalina de hemifumarato de alisquireno |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| AR066168A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2009040427A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP2062874B1 (en) * | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
-
2009
- 2009-09-22 AR ARP090103629A patent/AR073651A1/es unknown
- 2009-09-23 AU AU2009296718A patent/AU2009296718A1/en not_active Abandoned
- 2009-09-23 TW TW098132133A patent/TW201016210A/zh unknown
- 2009-09-23 US US13/120,182 patent/US20110177166A1/en not_active Abandoned
- 2009-09-23 CN CN2009801373641A patent/CN102164584A/zh active Pending
- 2009-09-23 MX MX2011003077A patent/MX2011003077A/es not_active Application Discontinuation
- 2009-09-23 CA CA2736259A patent/CA2736259A1/en not_active Abandoned
- 2009-09-23 EP EP09792885A patent/EP2328562A1/en not_active Withdrawn
- 2009-09-23 PE PE2011000667A patent/PE20110925A1/es not_active Application Discontinuation
- 2009-09-23 KR KR1020117009209A patent/KR20110063684A/ko not_active Withdrawn
- 2009-09-23 RU RU2011116122/15A patent/RU2011116122A/ru not_active Application Discontinuation
- 2009-09-23 JP JP2011529177A patent/JP2012503665A/ja active Pending
- 2009-09-23 WO PCT/US2009/057993 patent/WO2010036686A1/en not_active Ceased
- 2009-09-23 BR BRPI0919077A patent/BRPI0919077A2/pt not_active IP Right Cessation
-
2011
- 2011-03-04 ZA ZA2011/01686A patent/ZA201101686B/en unknown
- 2011-03-23 CL CL2011000614A patent/CL2011000614A1/es unknown
- 2011-03-25 CO CO11036970A patent/CO6351712A2/es not_active Application Discontinuation
- 2011-04-20 MA MA33785A patent/MA32722B1/fr unknown
- 2011-04-21 EC EC2011010998A patent/ECSP11010998A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11010998A (es) | 2011-06-30 |
| ZA201101686B (en) | 2012-01-25 |
| TW201016210A (en) | 2010-05-01 |
| JP2012503665A (ja) | 2012-02-09 |
| MA32722B1 (fr) | 2011-10-02 |
| WO2010036686A1 (en) | 2010-04-01 |
| AR073651A1 (es) | 2010-11-24 |
| KR20110063684A (ko) | 2011-06-13 |
| EP2328562A1 (en) | 2011-06-08 |
| US20110177166A1 (en) | 2011-07-21 |
| CA2736259A1 (en) | 2010-04-01 |
| BRPI0919077A2 (pt) | 2015-12-15 |
| MX2011003077A (es) | 2011-08-03 |
| CN102164584A (zh) | 2011-08-24 |
| CO6351712A2 (es) | 2011-12-20 |
| CL2011000614A1 (es) | 2011-11-04 |
| RU2011116122A (ru) | 2012-10-27 |
| AU2009296718A1 (en) | 2010-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
| PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
| MX2012003551A (es) | Tabletas transformables via oral. | |
| CR10349A (es) | Tabletas de paracetamol de liberacion rapida | |
| DOP2015000028A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| CL2014001029A1 (es) | Forma de dosificacion farmaceutica solida oral de liberacion extendida que comprende una formulacion matricial que comprende un agente activo en forma de comprimido o multiparticulado; agente activo es un analgesico opioide; y uso en el tratamiento del dolor. (div. sol. 499-2012). | |
| AR078417A1 (es) | Composiciones de pelicula sublingual y bucal | |
| CL2011000642A1 (es) | Unidad de dosificacion que comprende 25 a 400 mg del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico; kit farmaceutico que comprende la unidad de dosificacion; y su uso para el tratamiento de fibrosis quistica. | |
| CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
| ECSP10010416A (es) | Forma de dosificación farmaceutica | |
| PE20110893A1 (es) | Formulacion farmaceutica que contiene 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluorobencil]-2h-ftalazin-1-ona | |
| UY30961A1 (es) | Comprimido famacéutico, capa de comprimido comprendiendo ingrediente activo telmisartan, un agente basico y sorbitol, proceso de preparacion y aplicaciones, | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| BRPI0819719A2 (pt) | Compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e peparações farmacêuticas contendo os mesmos como agente ativo | |
| AR086249A1 (es) | Composiciones de tabletas de disolucion rapida de administracion vaginal | |
| AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
| PE20110925A1 (es) | Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida | |
| BR112012029064A2 (pt) | formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan | |
| CO6640264A2 (es) | Combinación de gránulos cargados activos con activos adicionales | |
| AR062925A1 (es) | Metodo para fabricar tabletas que contienen agentes farmacologicamente activos | |
| PE20080673A1 (es) | Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina | |
| PE20130403A1 (es) | Comprimido de desintegracion via oral que contiene acarbosa | |
| PE20120647A1 (es) | Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |